ID | 1025 |
Name of the vaccine | EasyFive-TT |
Microbe | Bacteria |
Disease name | Diphtheria |
Name of bacteria | Corynebacterium diphtheriae |
Type of vaccine | Combination |
Nucleic acid content | DNA |
Age | From 6 weeks |
Description of the vaccine | Pentavalent vaccine (DTwP-HepB-Hib). |
Name of the manufacturer | Panacea Biotech Ltd. |
Name of the manufacturing country | India |
Year of manufacture | 2009 |
Clinical Phase status | Approved |
Bacterial strain | Gram-positive bacillus. |
Efficacy | The anti-diphtheria seroprotection rate was 97.7%. |
Vaccine formulation | Sterile and uniform suspension. |
Dosage | First dose as early as 6 weeks and two subsequent doses given at 4 week interval. |
Mechanism of action | NA |
Route of administration | Intramuscular |
Indications | Immunization against diphtheria, tetanus, whole cell pertussis, hepatitis B and Haemophilus influenzae type b infections. |
Export | Marketing Authorisation Holder: Panacea Biotech Ltd, India |
Approval | WHO |
Adjuvant | Aluminium phosphate |
Repurposing | For pertussis, Hib, tetanus, hepatitis B. |
Side effects of vaccine | Temporary swelling, tenderness and redness with fever, feeding disorders, sleepiness, irritability. |
Post vaccination | NA |
Dose type | Combination doses |
Interspecies transfer | NA |
PubMed identifier | NA |
Clinical trial number | NA |
Reference | https://www.who.int/immunization_standards/vaccine_quality/pq_270_penta_panacea_10dose_product_insert.pdf?ua=1 |
Other name | NA |
Additional Links | https://cdsco.gov.in/opencms/resources/UploadCDSCOWeb/2018/UploadSmPC/1850ml.pdf
|